FDA accepts New Drug Application for casimersen for treatment of patients with Duchenne Muscular Dystrophy amenable to skipping exon 45 of dystrophin gene.

Submission includes data from the casimersen arm of ongoing ESSENCE study, an interim analysis of which demonstrated a statistically significant increase in dystrophin production as measured by western blot in patients who received casimersen compared to baseline and placebo.


Biospace Inc.